Liquidia (NASDAQ:LQDA) Price Target Raised to $25.00

Liquidia (NASDAQ:LQDA) had its target price increased by analysts at Needham & Company LLC from $19.00 to $25.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective indicates a potential upside of 67.56% from the company’s current price.

Other equities research analysts have also issued research reports about the company. Wells Fargo & Company started coverage on Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Liquidia in a report on Thursday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $26.13.

Liquidia Trading Up 1.2 %

Liquidia stock opened at $14.92 on Thursday. The firm has a market capitalization of $1.26 billion, a P/E ratio of -9.15 and a beta of 0.07. Liquidia has a twelve month low of $8.26 and a twelve month high of $16.99. The stock’s fifty day simple moving average is $14.67 and its 200-day simple moving average is $12.12.

Insider Transactions at Liquidia

In other news, General Counsel Russell Schundler sold 16,393 shares of the business’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the completion of the sale, the general counsel now directly owns 573,478 shares of the company’s stock, valued at approximately $6,755,570.84. The trade was a 2.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajeev Saggar sold 2,445 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total value of $31,785.00. Following the transaction, the insider now owns 267,943 shares in the company, valued at $3,483,259. This represents a 0.90 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,245 shares of company stock worth $843,326. 30.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Liquidia

A number of institutional investors have recently modified their holdings of LQDA. LM Advisors LLC purchased a new position in Liquidia during the 4th quarter worth $25,948,000. Whitefort Capital Management LP grew its holdings in shares of Liquidia by 119.8% during the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after buying an additional 927,546 shares during the last quarter. Invesco Ltd. increased its position in Liquidia by 2,675.0% in the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company’s stock valued at $8,234,000 after acquiring an additional 674,940 shares during the period. Janus Henderson Group PLC raised its stake in Liquidia by 1,484.5% during the 4th quarter. Janus Henderson Group PLC now owns 535,552 shares of the company’s stock valued at $6,293,000 after acquiring an additional 501,752 shares during the last quarter. Finally, Mirabella Financial Services LLP acquired a new stake in Liquidia during the 4th quarter worth approximately $5,880,000. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).